vena punction

PreclinicalBiologic

EErasmus Medical Center

vena punction is one of 4 biologic programs targeting Epilepsy Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epilepsy SyndromeActive, not recruiting

Epilepsy SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Epilepsy Syndrome

#DrugCompanyPhaseTrials

Fintepla

Vimpat

1 3

Sulthiame

Roche

Preclinical

1 4

vena punction

EErasmus Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epilepsy Syndrome1 trial

Antibodies Causing Epilepsy Syndromes: The ACES Study.

Completed·EErasmus Medical Center··NCT02802475·582 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for vena punction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vena punction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vena punction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Erasmus Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: EErasmus Medical Center

vena punction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epilepsy Syndrome1 trial

References

Drug Info

Quick Facts

Related News